🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 19 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 10/07/2002 | 14,85 | 15,07 | 12,67 | 12,95 | -13,03% | 16,16% | 1.270.300 |
| 09/07/2002 | 14,99 | 15,34 | 14,38 | 14,89 | -1,19% | 6,40% | 720.800 |
| 08/07/2002 | 15,70 | 15,98 | 15,06 | 15,07 | -4,50% | 5,86% | 446.700 |
| 05/07/2002 | 15,18 | 16,16 | 15,16 | 15,78 | +4,43% | 6,59% | 210.100 |
| 03/07/2002 | 14,45 | 15,50 | 14,01 | 15,11 | +2,65% | 10,31% | 859.900 |
| 02/07/2002 | 15,21 | 15,77 | 14,10 | 14,72 | -4,23% | 10,98% | 866.200 |
| 01/07/2002 | 16,50 | 16,91 | 15,10 | 15,37 | -5,59% | 10,97% | 732.900 |
| 28/06/2002 | 16,11 | 18,00 | 15,80 | 16,28 | +0,18% | 13,66% | 1.723.900 |
| 27/06/2002 | 15,92 | 16,72 | 15,68 | 16,25 | +2,20% | 6,53% | 781.000 |
| 26/06/2002 | 15,75 | 16,15 | 15,02 | 15,90 | -0,62% | 7,17% | 736.400 |
| 25/06/2002 | 16,80 | 17,10 | 15,65 | 16,00 | -2,56% | 8,63% | 901.100 |
| 24/06/2002 | 16,31 | 17,26 | 15,71 | 16,42 | +0,37% | 9,50% | 870.200 |
| 21/06/2002 | 16,88 | 17,40 | 16,11 | 16,36 | -2,62% | 7,64% | 851.800 |
| 20/06/2002 | 18,19 | 18,22 | 16,75 | 16,80 | -7,13% | 8,08% | 790.200 |
| 19/06/2002 | 18,68 | 19,11 | 18,03 | 18,09 | -3,62% | 5,78% | 632.900 |
| 18/06/2002 | 18,80 | 19,57 | 18,15 | 18,77 | +1,24% | 7,55% | 748.200 |
| 17/06/2002 | 17,87 | 19,19 | 17,75 | 18,54 | +3,98% | 8,06% | 702.600 |
| 14/06/2002 | 16,48 | 18,24 | 16,14 | 17,83 | +7,34% | 12,74% | 776.100 |
| 13/06/2002 | 15,97 | 17,34 | 15,80 | 16,61 | +2,40% | 9,64% | 1.030.600 |
| 12/06/2002 | 16,09 | 16,80 | 15,52 | 16,22 | +0,75% | 7,96% | 1.343.300 |
| 11/06/2002 | 17,74 | 18,14 | 16,00 | 16,10 | -8,94% | 12,06% | 765.700 |
| 10/06/2002 | 17,40 | 18,59 | 17,40 | 17,68 | +1,49% | 6,84% | 391.500 |
| 07/06/2002 | 16,89 | 17,95 | 16,33 | 17,42 | +0,99% | 9,59% | 695.000 |
| 06/06/2002 | 18,61 | 18,65 | 17,16 | 17,25 | -6,76% | 8,01% | 777.000 |
| 05/06/2002 | 18,12 | 18,94 | 17,90 | 18,50 | +1,54% | 5,74% | 397.500 |
| 04/06/2002 | 18,06 | 18,33 | 17,50 | 18,22 | -0,60% | 4,60% | 739.500 |
| 03/06/2002 | 19,72 | 19,73 | 18,21 | 18,33 | -7,10% | 7,71% | 542.700 |
| 31/05/2002 | 20,08 | 20,25 | 19,44 | 19,73 | -1,50% | 4,03% | 576.100 |
| 30/05/2002 | 19,54 | 20,08 | 19,40 | 20,03 | -0,25% | 3,48% | 629.500 |
| 29/05/2002 | 20,64 | 20,89 | 20,05 | 20,08 | -2,71% | 4,07% | 453.800 |